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While in RARS-T, JAK2V617F mutation is common and associated with good prognosis, the clinical and
prognostic impact of this mutation in other MDS is unknown. We collected data from 132 non-RARS-T
MDS with known JAK2V617F mutation status. JAK2V617F mutation was signiﬁcantly correlated with
lower progression to AML (po .0011) and better overall survival (OS, p¼ .011). OS difference persisted
after matching on age, sex, IPSS and % marrow blast (p¼ .031). Thus, in MDS other than RARS-T,
JAK2V617F mutation may be associated with favorable outcome.
& 2013 The Authors. Published by Elsevier Ltd.Open access under CC BY-NC-ND license.1. Introduction
Acquired JAK2V617F somatic mutation is a hallmark of Phila-
delphia negative myeloproliferative neoplasm (MPN) [1,2]. In
myelodysplastic syndromes (MDS), JAK2V617F mutation is seen
in less than 5% of the cases [3]. Both 2001 and 2008 WHO
classiﬁcations include among myelodysplastic/myeloproliferative
(MDS/MPN) overlap syndromes [4] a provisional entity, refractory
anemia with ringed sideroblasts associated with sustained throm-
bocytosis (RARS-T) that appears to have a relatively favorabler Ltd.
re et d'Hématologie Clinique
d, France.
.fr (B. de Renzis),
Open access under CC BY-NC-NDprognosis [5] especially if JAK2V617F mutation, detected in about
60% of the cases, is present [3]. Apart from RARS-T, however, the
impact of JAK2V617F mutation in MDS remains unknown [6–8].
We conducted a retrospective study of MDS patients with
JAK2V617F mutation, after exclusion of RARS-T cases, where
patients were compared with matched unmutated MDS without
JAK2V617F mutation.2. Materials/methods
2.1. Data collection
After approval by the Clermont-Ferrand University Hospital
Ethics committee, a questionnaire was sent to all French centers of
the Groupe Francophone des Myélodysplasies (GFM) and of the
French Intergroup of Myeloproliferative neoplasms (FIM) to collect
clinical, laboratory and follow up data in MDS patients with
known JAK2V617F mutation status detected in blood by real-
time polymerase chain reaction. We also obtained, from the GFM license.
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mutation had been tested. In the absence of speciﬁc recommenda-
tions, JAK2V617F mutation in those patients had been assessed
systematically at diagnosis in a few centers, or later in the disease
course, mainly because of features with potential predictive value
for JAK2V617Fmutation, like thrombocytosis. Patients with chronic
myelomonocytic leukemia, RARS-T and MDS following MPN were
excluded [4].2.2. Statistical analysis
Descriptive statistics were used to characterize the population
on parameters collected at the time of diagnosis. Overall survival
(OS) was deﬁned from diagnosis to death or censored at latest
contact with the patient. Time to acute myeloid leukemia (AML)
progression was deﬁned from diagnosis to date of AML. OS curves
and OS estimates were determined using the Kaplan–Meier
method. Patient characteristics and outcome according to
JAK2V617F mutation status were analyzed by univariate analysis
using the chi-square test for qualitative analysis and Kruskal–
Wallis test for quantitative analysis and log-rank test for OS
comparison.
The primary endpoint of this retrospective analysis was to
assess the impact of JAK2V617F mutation on MDS. In an attempt to
reduce the effect of potential bias in this cohort, propensity scoreTable 1
Clinical, laboratory features and outcome in MDS with or without JAK2V617 mutation.
JAK2V617F posit
Demographics and hematological features n¼37
Median age (range) 74 (47–93)
M/F 18/19a
Hb g/100 ml (median, range) 10.1 (6.3–14.2)
MCV ﬂ (median, range) 103 (82–125)
Median WBC G/L (range) 6.1 (1.9–17.4)
Median ANC G/L (range) 3.7 (.2–12.6)
Median platelet count G/L (range) 262 (35–1108)
Median % marrow blasts (range) 2 (0–16)
Karyotype n¼33
Normal 17 (51%)
Del 5q 4 (12%)
Del 20q 1 (3%)
+8 4 (12%)
7/del7q 1 (3%)
complex (n≥3) 6 (21%)
WHO 2008 classiﬁcation n¼37
RA 5 (13%)
RARS 8 (23%)
RCMD 9 (24%)
RAEB-1 7 (19%)
RAEB-2 3 (8%)
MDS with isolated del(5q) 2 (5%)
Unclassiﬁed 3 (8%)
IPSS n¼33
Low 13 (39%)
Intermediate-1 17 (52%)
Intermediate-2 3 (9%)
High 0 (0%)
Treatment n¼37
ESA 20 (54%)
Lenalidomide or thalidomide 9 (24%)
Intensive chemotherapy 4 (11%)
Hypomethylating agent 3 (8%)
Allogeneic transplant 1 (3%)
Abbreviations: M: male; F: female; MCV: mean corpuscular volume; WBC: white blood ce
with ring siderobalsts; CRMD: refractory cytopenia with multilineage dysplasia; RAEB-1:
blasts-2; MDS: myelodysplastic syndromes; IPSS: international prognostic scoring syste
a Data not available.matching was used. This method allows balancing of all measured
relevant variables between the 2 groups (JAK2V617F positive and
negative).
Covariates included in the propensity-score model were sex,
hemoglobin, WBC, ANC, platelet, IPSS, karyotype, marrow blasts
and age known to be clinical relevant in MDS. OS analysis was
performed with a Cox model adjusted with propensity score [9].
Statistical signiﬁcance was considered below .05. Statistical ana-
lysis was performed using STATA 10.0 software (StataCorp, College
Station, TX, USA).3. Results
Data from 132 MDS patients with known JAK2V617F mutation
status were collected in 19 centers of the FIM and GFM, including 37
JAK2V617F positive (JAK2+) and 95 JAK2V617F negative (JAK2) cases.
Their main clinical and laboratory features are presented in
Table 1. The JAK2V617F mutation burden was available in only
7 patients, showing a median level of 16% (range, 1–50%).
There were no signiﬁcant differences between JAK2+ and
JAK2 cases in terms of age, gender, hemoglobin level, WHO
2008 classiﬁcation, cytogenetic ﬁndings and IPSS. In JAK2+
patients, the white blood cells (WBC) count, absolute neutrophil
count (ANC), platelet count and mean corpuscular volume (MCV)ive JAK2V617F negative p
n¼95
70.5 (38–95) .44
49/46 .87
9.8 (6.5–14.5) .51
98 (77–124) .018
4.4 (.9–18.4) .004
2.1 (.3–15.8) .009
156 (5–663) .002
4 (0–19) o .001
n¼94
59 (63%) .52
5 (5%) .36
3 (3%) .62
3 (3%) .15
2 (2%) .69
10 (11%) .25
n¼95
24 (25%) .14
9 (9%) .11
13 (14%) .14
27 (28%) .26
19 (20%) .10
1 (1%) .39
3 (3%) .45
n¼94
32 (34%) .58
44 (47%) .64
13 (14%) .69
5 (5%) .41
n¼80
37 (46%) .43
9 (11%) .053
6 (7%) .67
5 (6%) .89
0
ll; ANC: absolute neutrophil count; RA: refractory anemia; RARS: refractory anemia
refractory anemia with excess of blasts-1; RAEB-2: refractory anemia with excess of
m; ESA: Erythropoiesis stimulating agent
Fig. 1. Overall survival according to JAK2V617F status in MDS.
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signiﬁcantly lower than in JAK2 cases.
Treatments used (Table 1) were similar in both patient groups,
especially with regards to erythropoietic stimulating agents,
chemotherapy and hypomethylating agents. Seventeen JAK2+
(45%) versus 36 (37.8%) JAK2 patients were red blood cell
transfusion-dependent (p¼ .77).
Median follow up was 44 months (range 18–349) in JAK2+ and
69 months (range 32–185) in JAK2 patients (p¼ .95). OS was
signiﬁcantly longer in JAK2+ patients (median not reached) than in
JAK2 patients (median 66 months) (p¼ .011) (Fig. 1). The
estimated 5-year OS was 86% in JAK2+ patients versus 57% in
JAK2 patients. The 10 year cumulative incidence of AML pro-
gression was signiﬁcantly lower in JAK2+ (20%) than in JAK2
patients (47%) (po .001).
When the analysis was matching with propensity score, OS was
still signiﬁcantly longer in JAK2+ patients (median not reached
versus 73 months, p¼ .031) whereas JAK2 status had no signiﬁcant
prognostic value for OS in IPSS intermediate-2 and high patients
(p¼ .18).4. Discussion
In this series, which is to our knowledge the ﬁrst to focus on
MDS with JAK2V617F mutation other than RARS-T, we found JAK2+
cases to have higher WBC, ANC and platelet counts and fewer
marrow blasts than JAK2 MDS, but no signiﬁcant difference in
cytogenetics and IPSS.
JAK2+cases had signiﬁcantly lower risk of AML progression and
better OS than JAK 2 patients, an OS advantage which persistedin a matched case control analysis based on age, gender, marrow
blast percentage and IPSS.
Recently, in a large series of 439 MDS, Bejar et al. found no
prognostic value to JAK2V617F mutation but only 13 (3%) of the
patients had JAK2V617F mutation. In addition, whether some of
those patients had RARS-T was not indicated [10]. Finally, only 64%
of the JAK2+ cases had lower risk IPSS in Bejar et al. series,
compared to 80% in our study. Indeed, we found the favorable
prognosis of JAK2V617F mutation to be mainly restricted to lower
risk IPSS.
Thus, we found that MDS other than RARS-T with JAK2V617F
mutation were associated with laboratory features (higher WBC,
ANC, platelet count) with better outcome. However, prospective
studies precisely evaluating the impact of this mutation are
required to conﬁrm our ﬁndings.Acknowledgments
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